MBL files first ANDA in eCTD format for BORTEZOMIB injection 3.5 MG/VIAL with USFDA. R&D team internally develops API, Shivalik Rasayan Ltd files DMF with USFDA. MBL authorised to use API for manufacturing injection. SEBI (LODR) Regulations, 2015 requirements met. Shares up 5.12% to Rs 755.30.

Medicamen Biotech’s USFDA filing sparks 5.12 per cent surge in shares

Medicamen stated that this represents a significant achievement for the company, which will eventually lead to a USFDA Audit.

Medicamen Biotech gains on successful ANDA filing for Bortezomib injections

Till now the company was focused on international markets

Medicamen Biotech announces debut in domestic pharma sector

Uniphos Enterprises Ltd, Shivalik Rasayan Ltd, Medicamen Biotech Ltd and Peninsula Land Ltd are among the other gainers in the BSE’s ‘B’ group today, 26 August 2022.

Aarvee Denims & Exports Ltd leads gainers in ‘B’ group

Vital Pharma Nordic is led by highly experienced specialists and engaged in licensing, development, distribution and sales of specialty Gx pharmaceuticals. VPN operate in the Nordic region now expanding internationally.

Medicamen Biotech signs CDMO agreement with Vital Pharma Nordic

The company had signed an agreement with the Tirupati Reality & Developers on October 14, 2020.

Medi Caps gets approval under RERA for Real Estate Project ‘Medicaps Business Park’

Medicamen Biotech hit a new high of Rs 948.95, having rallied 13 per cent on the BSE in Thursday’s intra-day deal.

This smallcap pharmaceutical stock has zoomed 62% thus far in December

AksharChem (India) Ltd, DE Nora India Ltd, Zee Learn Ltd and Medicamen Biotech Ltd are among the other gainers in the BSE’s ‘B’ group today, 03 December 2021.

Starlit Power Systems Ltd leads gainers in ‘B’ group

Medicamen Biotech consolidated net profit rises 31.06% in the September 2021 quarter

Medicamen Biotech standalone net profit rises 31.06% in the September 2021 quarter

Medi Caps consolidated net profit rises 58.77% in the June 2021 quarter

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced and in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Not a good time to consider, stock is in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

MEDICAMEN Biotech is engaged in manufacturing of pharmaceutical formulations.